Adagene Inc.
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
0
Ending by 2030
Dec 2034
Next term end
When these terms end
Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due Jan 4, 2027The maintenance fee for Anti-CTLA4 antibodies and methods of making and using the same (US 11,692,036) comes due Jan 4, 2027. Unpaid by Jul 6, 2027, it lapses early.
- 1 fee due Jul 2, 2027The maintenance fee for Method for Treating Cancer Using ANTI-CD137 Antibody (US 11,859,003) comes due Jul 2, 2027. Unpaid by Jan 3, 2028, it lapses early.
- 1 fee due Oct 9, 2027The maintenance fee for Masked Activatable CD137 Antibodies (US 11,952,681) comes due Oct 9, 2027. Unpaid by Apr 10, 2028, it lapses early.
Recent changes
- 1 of the patents on this record was granted since Aug 16, 2026
Patents held now
Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 11,485,977 | Methods and systems for autoinduction of protein expression In force · From the USPTO record | In force | From the USPTO record | |
| US 12,503,693 | Integrated system for library construction, affinity binder screening and expression thereof In force · From the USPTO record | In force | From the USPTO record | |
| US 11,242,395 | ANTI-CD137 Molecules and Use Thereof In force · High confidence | In force | High confidence | |
| US 11,859,003 | Method for Treating Cancer Using ANTI-CD137 Antibody In force · High confidence | In force | High confidence | |
| US 12,378,319 | ANTI-CD137 Molecules and Use Thereof In force · High confidence | In force | High confidence | |
| US 12,385,162 | Dynamic Human Heavy Chain Antibody Libraries In force · High confidence | In force | High confidence | |
| US 11,585,014 | Dynamic Human Antibody Light Chain Libraries In force · High confidence | In force | High confidence | |
| US 11,578,426 | Dynamic Human Heavy Chain Antibody Libraries In force · High confidence | In force | High confidence | |
| US 11,359,016 | Anti-CTLA4 antibodies and methods of making and using the same In force · From the USPTO record | In force | From the USPTO record | |
| US 11,952,681 | Masked Activatable CD137 Antibodies In force · High confidence | In force | High confidence |
Sources and methods
Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand.
How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
Published applications
US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.
3 pending · 1 abandoned · 4 no status recorded